Alnylam Pharmaceuticals
ALNY
#634
Rank
S$41.23 B
Marketcap
$318.61
Share price
0.26%
Change (1 day)
62.77%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -S$0.32 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are S$2.24 Billion. , an increase over its 2023 earnings that were of -S$0.42 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 -S$0.31 Billion-24.59%
2023 -S$0.42 Billion-67.84%
2022 -S$1.28 Billion36.93%
2021 -S$0.94 Billion-8.04%
2020 -S$1.02 Billion-15.66%
2019 -S$1.21 Billion12.23%
2018 -S$1.07 Billion62.91%
2017 -S$0.66 Billion17.78%
2016 -S$0.56 Billion43.44%
2015 -S$0.39 Billion60.69%
2014 -S$0.25 Billion98.2%
2013 -S$0.13 Billion
2011 -S$72 Million27.48%
2010 -S$56.48 Million-10.92%
2009 -S$63.4 Million95.77%
2008 -S$32.39 Million
2006 -S$51.88 Million-9.13%
2005 -S$57.1 Million34.74%
2004 -S$42.38 Million36.79%
2003 -S$30.98 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-S$0.79 Billion 154.87%๐Ÿ‡บ๐Ÿ‡ธ USA
S$6.27 B-2,129.54%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.34 B-210.72%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$13.61 Million-95.60%๐Ÿ‡บ๐Ÿ‡ธ USA
-S$60.68 Million-80.38%๐Ÿ‡บ๐Ÿ‡ธ USA
S$17.91 B-5,891.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
S$10.43 B-3,472.17%๐Ÿ‡ซ๐Ÿ‡ท France
-S$0.38 Billion 19.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel